Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother's risk of delivering spontaneously. It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics Inc.

Sera Prognostics, Inc. (($SERA)) has held its Q1 earnings call. Read on for the main highlights of the call. Sera Prognostics’ latest earnings call...

Sera Prognostics Balances Cash Strength With Slow Ramp

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vir Biotechnology (VIR), Gilead Sciences (GILD) and ...

Current Quarter	$-0.14	Next Quarter	$-0.14
Current Year	$-0.58	Next Year	$-0.51
QoQ Growth	+0.0%	YoY Growth	+12.1%
3Y EPS CAGR	+22.3%	Target Price	$5.00
Consensus	Buy	Upside	+132.6%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SERA	$2.15	+3.86%	133.79K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SERA	$2.15	+3.9%	133.79K
3
4
5
6

SERA

SERA

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Sera Prognostics Inc. Data in Excel

Get Sera Prognostics Inc. Data in Excel